Stuart J. Perper
Biogen Idec
8 Papers
30 Citations
Stuart J. Perper is an academic researcher from Biogen Idec. The author has contributed to research in topics: Inflammation & Experimental autoimmune encephalomyelitis. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
TWEAK Is a Novel Arthritogenic Mediator
Stuart J. Perper,Beth Browning,Linda C. Burkly,Shawn Weng,Cindy Gao,Keith Giza,Lihe Su,Leticia Tarilonte,Thomas Crowell,Luis Rajman,Laura Runkel,Martin L. Scott,Gerald J. Atkins,David M. Findlay,Timothy S. Zheng,Henry Hess +15 more
TL;DR: It is demonstrated that TWEAK induced the production of matrix metalloproteases in human chondrocytes and potently inhibited chondrogenesis and osteogenesis using in vitro models, and provided evidence for a novel cytokine pathway that contributes to joint tissue inflammation, angiogenesis, and damage.
158
An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis.
Diane R Leone,Keith Giza,Alan Gill,Brian M. Dolinski,W. Yang,Stuart J. Perper,Daniel Scott,Wen-Cherng Lee,Mark Cornebise,K. Wortham,C. Nickerson-Nutter,L. L. Chen,Doreen Lepage,J. C. Spell,Eric T. Whalley,Russell C. Petter,Steve Adams,Roy R. Lobb,R. B. Pepinsky +18 more
TL;DR: It is demonstrated that BIO5192, a novel, potent, and selective inhibitor of α4 β1 integrin, will be a valuable reagent for assessing α4β1 biology and may provide a new therapeutic for treatment of human inflammatory diseases.
64
A mouse Fcγ-Fcε protein that inhibits mast cells through activation of FcγRIIB, SH2 domain–containing inositol phosphatase 1, and SH2 domain–containing protein tyrosine phosphatases
Elisabeth Mertsching,Lisa Bafetti,Henry Hess,Stuart J. Perper,Keith Giza,Lisa Chan Allen,Ella Negrou,Karen Hathaway,Jennifer Hopp,Julie Chung,Daniel Perret,Michael Shields,Andrew Saxon,Marilyn R. Kehry +13 more
TL;DR: In this article, a human Fcγ-Fce fusion protein (GE2) designed to inhibit FceRI signaling was shown to inhibit mast cell activation and block cutaneous anaphylaxis.
36
Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
R. B. Pepinsky,Wen-Cherng Lee,Mark Cornebise,Alan Gill,K. Wortham,L. L. Chen,Diane R Leone,Keith Giza,Brian M. Dolinski,Stuart J. Perper,C. Nickerson-Nutter,Doreen Lepage,A. Chakraborty,Eric T. Whalley,Petter Russell C,Steve Adams,Roy R. Lobb,Daniel Scott +17 more
TL;DR: The studies demonstrate the feasibility of PEGylation of α4β1-targeted small molecules with retention of activity in vitro and in vivo and may provide a new therapeutic approach to treatment of human inflammatory diseases.
29
Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus.
Stuart J. Perper,Susan V. Westmoreland,Jozsef Karman,Rachel Twomey,Jane Seagal,Rui Wang,Bradford L. McRae,Stephen H. Clarke +7 more
TL;DR: This ability to disrupt disease-critical immunological mechanisms, to reverse glomerular and tubular injury at the cellular and gene expression levels, and to confer exceptional therapeutic efficacy suggests that CD40 is a central disease pathway in murine SLE.
29